XORTX Therapeutics Inc. unveils investor presentation on gout and kidney disease drug pipeline
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc. has released an investor presentation detailing its lead product candidate, XRx-026, aimed at treating gout, with an NDA submission planned for the first half of 2026. The formulation has been tested in over 700 patients, showing safety and efficacy, especially for those intolerant to allopurinol. The presentation also covers the company's pipeline, including XRx-008 for autosomal dominant polycystic kidney disease, and discusses the competitive landscape for gout therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments